IVIG Toolkit

Primary Immunodeficiency is caused by inherent defects of the immune system. It results in recurrent, severe or unusual infections. Intravenous immunoglobulin (IVIG) treatment can preserve organ function, improve quality of life, prevent infection-related death and increase lifespan.

This IVIG toolkit is a resource for educating payers and regulators responsible for coverage determinations and also aids physicians in the safe, effective and appropriate use of IVIG for patients with primary immunodeficiency diseases (PIDD) This toolkit has been approved by the AAAAI Board of Directors, and endorsed by the Clinical Immunology Society (CIS) and the Immune Deficiency Foundation (IDF).

We are in the process of updating this page. Please check back for up dates.